{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:00:10Z","timestamp":1793412010738,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN272201000052I"],"award-info":[{"award-number":["HHSN272201000052I"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN272200900052C"],"award-info":[{"award-number":["HHSN272200900052C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23-AI-104780"],"award-info":[{"award-number":["K23-AI-104780"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UL1TR001082"],"award-info":[{"award-number":["UL1TR001082"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["NCRR\/NIH 1UL1RR025780"],"award-info":[{"award-number":["NCRR\/NIH 1UL1RR025780"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UL1TR000075"],"award-info":[{"award-number":["UL1TR000075"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R01AI098077"],"award-info":[{"award-number":["5R01AI098077"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["N01-AI-90052"],"award-info":[{"award-number":["N01-AI-90052"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UL1TR000077-04"],"award-info":[{"award-number":["UL1TR000077-04"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016259","name":"Mylan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jaip.2020.03.051","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T21:11:36Z","timestamp":1588540296000},"page":"3021-3028.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma"],"prefix":"10.1016","volume":"8","author":[{"given":"William J.","family":"Sheehan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Z.","family":"Krouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Calatroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Gergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Gern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Gruchalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjit K.","family":"Khurana Hershey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meyer","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Kercsmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin I.","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic F.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"Makhija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Searing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Zoratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Teach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.03.051_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.iac.2014.09.006","article-title":"Inner city asthma","volume":"35","author":"Gergen","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2020.03.051_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/ped.2018.0901","article-title":"Current state and future of biologic therapies in the treatment of asthma in children","volume":"31","author":"Abrams","year":"2018","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.jaip.2020.03.051_bib3","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMct055184","article-title":"Omalizumab for asthma","volume":"354","author":"Strunk","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.03.051_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.03.051_bib5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.03.051_bib6","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2020.03.051_bib7","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.03.051_bib8","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2020.03.051_bib9","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2020.03.051_bib10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.03.051_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.03.051_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.03.051_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaip.2013.01.011","article-title":"Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents","volume":"1","author":"Sorkness","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"Suppl","key":"10.1016\/j.jaip.2020.03.051_bib14","first-page":"S94","article-title":"Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007","volume":"120","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.03.051_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.03.051_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1515\/ijb-2015-0032","article-title":"Model-based recursive partitioning for subgroup analyses","volume":"12","author":"Seibold","year":"2016","journal-title":"Int J Biostat"},{"key":"10.1016\/j.jaip.2020.03.051_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/ACI.0000000000000517","article-title":"Precision medicine in childhood asthma","volume":"19","author":"Slob","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.03.051_bib18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1398-9995.2010.02336.x","article-title":"The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective","volume":"65","author":"Campbell","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.03.051_bib19","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jaci.2014.12.1942","article-title":"Seasonal risk factors for asthma exacerbations among inner-city children","volume":"135","author":"Teach","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.03.051_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1183\/09031936.00165106","article-title":"Severe exacerbations predict excess lung function decline in asthma","volume":"30","author":"Bai","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.03.051_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2012.01.039","article-title":"Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma","volume":"129","author":"Ivanova","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820304141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820304141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:51:09Z","timestamp":1778853069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820304141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2213219820304141"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.03.051","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.03.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}